Trump's NIH cuts are gutting university labs that fuel Big Pharma's drug pipeline and pushing U.S. biotech jobs, research, ...

AstraZeneca is making a bold move. The drug giant just teamed up with CSPC in a deal worth up to $5.3 billion. The goal? To ...

Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...